الرئيسية › الورم النقوي المتعدد › تكساس › Houston
التجارب السريرية لـ الورم النقوي المتعدد في Houston، TX
38 دراسات لـ الورم النقوي المتعدد تبحث عن مشاركين في مواقع داخل وحول Houston (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
جارٍ التسجيلالمرحلة 3
- Research Site, Houston
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
جارٍ التسجيلالمرحلة 1
- MD Anderson Cancer Center, Houston
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
جارٍ التسجيلالمرحلة 1
- Research Site, Houston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- MD Anderson Cancer Center, Houston
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1/2
- MD Anderson, Houston
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
جارٍ التسجيلالمرحلة 3
- Houston Methodist Hospital, Houston
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
جارٍ التسجيلالمرحلة 3
- The University of Texas MD Anderson Cancer Center, Houston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
جارٍ التسجيلالمرحلة 4
- MD Anderson Cancer Center, Houston
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
جارٍ التسجيلالمرحلة 2
- The University of Texas MD Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
جارٍ التسجيلالمرحلة 3
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
جارٍ التسجيلالمرحلة 2
- MD Anderson Cancer Center, Houston
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1/2
- MD Anderson Cancer Center, Houston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
جارٍ التسجيلالمرحلة 3
- University of Texas MD Anderson Cancer Center, Houston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1/2
- Research Site, Houston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
جارٍ التسجيلالمرحلة 3
- Houston Methodist Cancer Center Infusion, Houston
- Houston Methodist Hospital - Department of Pharmacy, Houston
- Houston Methodist Hospital Cancer Center, Houston
- و 3 أخرى
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
جارٍ التسجيلالمرحلة 1/2
- MD Anderson Cancer Center, Houston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
جارٍ التسجيلالمرحلة 1/2
- Research Site, Houston
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
جارٍ التسجيلالمرحلة 2مرحباً بالمتطوعين الأصحاء
- MD Anderson Cancer Center, Houston
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
جارٍ التسجيلالمرحلة 3
- Research Site, Houston
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
جارٍ التسجيلالمرحلة 1
- Houston Methodist Hospital, Houston
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1/2
- M D Anderson Cancer Center, Houston
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
جارٍ التسجيلالمرحلة 1/2
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- University of Texas MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 1
- Oncology Consultants /ID# 268323, Houston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
جارٍ التسجيلالمرحلة 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- M D Anderson Cancer Center, Houston
- و 2 أخرى
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
جارٍ التسجيلالمرحلة 2
- M D Anderson Cancer Center, Houston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
جارٍ التسجيلالمرحلة 3
- Houston Methodist Hospital, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
جارٍ التسجيلدراسة رصدية
- M D Anderson Cancer Center, Houston
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
جارٍ التسجيلالمرحلة 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
جارٍ التسجيلالمرحلة 1
- MD Anderson Cancer Center, Houston
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
جارٍ التسجيلالمرحلة 2
- M D Anderson Cancer Center, Houston
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
جارٍ التسجيلالمرحلة 1/2
- Houston Methodist Neal Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
جارٍ التسجيلالمرحلة 1/2
- MDACC, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
جارٍ التسجيلالمرحلة 1/2
- University of Texas MD Anderson Cancer Center, Houston
تجارب الورم النقوي المتعدد في مدن أخرى
- New York City, NY60 دراسات
- Boston, MA42 دراسات
- Atlanta, GA41 دراسات
- Durham, NC37 دراسات
- Nashville, TN32 دراسات
- Denver, CO27 دراسات
- Rochester, MN24 دراسات
- St. Louis, MO24 دراسات
- Columbus, OH24 دراسات
- Baldwin Park, CA23 دراسات
- Chicago, IL22 دراسات
- Seattle, WA22 دراسات
دراسات أخرى في Houston
- سرطان الرئة غير صغير الخلايا145 دراسات
- سرطان الثدي126 دراسات
- السرطان (جميع الأنواع)121 دراسات
- السرطان النقيلي104 دراسات
- سرطان القولون والمستقيم102 دراسات
- سرطان المبيض89 دراسات
- ابيضاض الدم النقوي الحاد85 دراسات
- سرطان الرئة78 دراسات
- سرطان البروستاتا76 دراسات
- سرطان بطانة الرحم68 دراسات
- سرطان البنكرياس61 دراسات
- ميلانوما59 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 05/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.